Homeostatic Microglial Reprogramming for Neuroinflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases associated with inflammation, such as Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis, are inadequate, particularly for progressive forms of Multiple Sclerosis, where microglial activation drives pro-inflammatory processes.
Innovation Solution
Reprogram peripheral blood monocytes into M0-homeostatic tolerogenic microglial cells using TGFβ and IFNγ signaling, optionally silencing APOE expression via CRISPR-Cas9, to induce a homeostatic microglial phenotype capable of reducing inflammation and promoting remyelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peripheral blood monocytes are reprogrammed into M0-homeostatic tolerogenic microglial cells using TGFβ and IFNγ signaling, then neuroinflammation is reduced and myelin phagocytosis is enhanced, but the process requires complex culture conditions and cytokine combinations
Solution Approach 1:
The patent applies parameter changes by utilizing specific cytokine combinations (TGFβ and IFNγ) at defined concentrations and durations to transform monocyte phenotype. The culture conditions are optimized with specific growth factors, supplements, and temporal parameters to achieve reliable generation of homeostatic microglial cells with desired functional properties.
Solution Approach 2:
The patent employs intermediary substances including TGFβ, IFNγ, and other cytokines as mediators to guide the reprogramming process. These intermediaries facilitate the transition from monocyte to homeostatic microglial phenotype by activating specific signaling pathways and suppressing others, enabling controlled differentiation.
2Reliability
If APOE expression is silenced via CRISPR-Cas9 to enhance homeostatic phenotype, then microglial function is improved, but the procedure becomes more complex and time-consuming
Solution Approach 1:
The patent replaces traditional mechanical or chemical gene silencing methods with CRISPR-Cas9 genome editing technology. This allows precise, permanent modification of the APOE gene sequence to eliminate expression, providing more reliable and durable functional stabilization compared to transient chemical inhibition methods.
Solution Approach 2:
The CRISPR-Cas9 system introduces parameter changes at the genetic level by creating specific mutations or deletions in the APOE gene. This genomic modification permanently alters the gene's expression pattern, ensuring stable functional properties in the engineered microglial cells throughout their lifespan.
3Duration of action of moving object
If reprogrammed microglial cells are administered to treat inflammatory neurodegenerative diseases, then disease progression is slowed, but the cells must be maintained in specific culture conditions throughout the process
Solution Approach 1:
The patent applies preliminary action by pre-reprogramming monocytes into homeostatic microglial cells with desired functional properties before administration to patients. The cells are generated, characterized, and prepared in advance under controlled culture conditions, ensuring they are ready for immediate therapeutic use upon administration.
Solution Approach 2:
The reprogrammed microglial cells exhibit self-service properties by autonomously performing their therapeutic functions in the patient's CNS without requiring continuous external support. Once administered, the cells maintain their homeostatic phenotype and functional activity independently, eliminating the need for continuous culture condition maintenance during therapeutic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reprogrammed microglial cells effectively reduce neuroinflammation and enhance myelin and synaptosome phagocytosis, potentially slowing or halting disease progression and improving neurological functions.
Implementation Method 1
maintaining the PBMC in culture ex vivo in the presence of a sufficient amount of transforming growth factor-beta (TGFβ) and interferon-gamma (IFNγ) for a time and under conditions sufficient for the cells to become M0-homeostatic tolerogenic microglia
Implementation Method 2
engineering the cells to reduce or eliminate expression of apolipoprotein E (APOE), e.g., using a CRISPR-Cas RNA-guided nuclease to induce a mutation that reduces or eliminates expression of APOE
Implementation Method 3
The reprogrammed microglial cells effectively reduce neuroinflammation and enhance myelin and synaptosome phagocytosis
Data Source
AI summary
Provided herein are methods for obtaining populations of reprogrammed M0-homeostatic tolerogenic microglial cells. The methods include providing an initial population of monocytes, e.g., peripheral blood monocytes (PBMC), from a subject, and reprogramming the cells by maintaining the PBMC in culture ex vivo in the presence of a sufficient amount of transforming growth factor-beta (TGFβ) and interferon-gamma (IFNγ) for a time and under conditions sufficient for the cells to become M0-homeostatic tolerogenic microglia. Also provided are methods of use of these cells, e.g., for the treatment of neurodegenerative diseases associated with inflammation, e.g., Alzheimer's Disease (AD); Multiple Sclerosis (MS), e.g., progressive MS; and Amyotrophic Lateral Sclerosis (ALS).